/compare — side-by-sideLOADING

compare stocks // side-by-side, from filings

Compare any stocks, on the real numbers

Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.

Metric	CATXPerspective Therapeu
Last close	$0.88close 2026-11-03
Change %	-15.38%close 2026-11-03
Market cap	$100Mclose 2026-11-03
P/E	loss, no P/E
Revenue	$1M ⊙ EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenueFromContractWithCustomerIncludingAssessedTax As ofFY ending 2023-12-31 Filing10-K · 0001437749-24-009696 · filed 2024-03-28 Open the filing on EDGAR →Open the XBRL payload → CitePerspective Therapeutics, Inc. (CATX), us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax: 1,434,000 USD, fiscal year ended 2023-12-31. Form 10-K, accession 0001437749-24-009696, filed 2024-03-28. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0000728387/us-gaap/RevenueFromContractWithCustomerIncludingAssessedTax.json

Share this comparisonSend CATX side-by-side — free, straight from the filings.

Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.